DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
CALADRIO
Gut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIO
BREAST
ESMO Breast
2022
PECATI
A phase 2 trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma
THYMIC
ESMO
2022
REVERT
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study
BREAST
(Journal) Cancers
2022
METALLICA
Metformin (MET) for the prevention of Alpelisib (ALP)-related Hyperglycemia (HG) in PIK3CA-mutated, Hormone Receptor-Positive (HR[+]) HER2-Negative (HER2[-]) Advanced Breast Cancer (ABC): The METALLICA study.
BREAST
SABCS
2022
REVERT
A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy (REVERT).
BREAST
ESMO
2022
ZZFIRST
A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide(EZ) and talazoparib (TALA) for the treatment of metastatichormone-naïve prostate cancer (mHNPC): ZZFIRST
PROSTATE
ASCO GU
2022
ORPHEUS
A phase 2 study of the efficacy and safety of INCMGA00012 in advanced penile squamous cell carcinoma (PSqCC): ORPHEUS
PENILE
ASCO GU
2022
LUPER
A Phase 1/2 Trial of Lurbinectedin (L) in Combination with Pembrolizumab (P) in Relapsed Small Cell Lung Cancer (SCLC): The LUPER Study.
LUNG
ASCO
2022
PHERGAIN
Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial
BREAST
ESMO Breast
2022
ATRACTIB
Safety Interim Analysis (SIA) of ATRACTIB: A Phase 2 Trial of First-Line (1L) Atezolizumab (A) in Combination with Paclitaxel (P) and Bevacizumab (B) in Metastatic Triple-Negative Breast Cancer (mTNBC).
BREAST
ASCO
2022
EXCAAPE
Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial
PROSTATE
(Journal) European Journal of Cancer
2022
PHERGAIN
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study
BREAST
(Journal) Future Oncology
2022
Other MEDSIR related articles
